KevinJ.CurranMD

Pediatric Hematology & Oncology • New York, NY

Physician

Overview of Dr. Curran

Dr. Kevin Curran is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital. He received his medical degree from Georgetown University School of Medicine and has been in practice 13 years. Dr. Curran accepts several types of health insurance, listed below. He is one of 95 doctors at Memorial Sloan Kettering Cancer Center and one of 135 doctors at New York-Presbyterian Hospital who specialize in Pediatric Hematology & Oncology. He has more than 80 publications and over 500 citings.

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(507) 581-8701

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2007 - 2010
Tufts Medical CenterResidency, Pediatrics, 2004 - 2007
Georgetown University School of MedicineClass of 2004

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2007 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies Start of enrollment: 2011 Sep 01
Active, not recruiting
Phase 1
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Start of enrollment: 2013 May 01
Active, not recruiting
Phase 1
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy Start of enrollment: 2017 Dec 29
Recruiting
Phase 3
Roles: Contact
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) Start of enrollment: 2022 Jul 12
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant Start of enrollment: 2021 Apr 30
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases Start of enrollment: 2021 Jul 14
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.
Monica S Nair, Sara K Silbert, Kai Rejeski, Karilynn A Wilson, Adam Joseph Lamble
Blood. 2024-11-19
Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelod...
Nancy A Kernan, Elizabeth Klein, Audrey Mauguen, Joanne Torok-Castanza, Susan E Prockop
Transplantation and Cellular Therapy. 2024-07-01
Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation.
Hannah Major-Monfried, Kinga Hosszu, Devin P McAvoy, Alexander Vallone, Neerav Shukla
Cytotherapy. 2024-05-01

Abstracts/Posters

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL
Kevin J. Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
Kevin J. Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Clinical Application of Cell Therapies: Mechanism of Action, Efficacy and Patient Selection. Hematologic Malignancies and CAR-T Cell Therapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Press Mentions

Turn Biotechnologies Announces Landmark Study to Assess Effectiveness of ERA™ Therapy in Restoring Bone MarrowDecember 3rd, 2024
Longevity Investment Bulletin: Mikra, Celmatix, LyGenesis and MoreApril 14th, 2023

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois Blue Advantage HMO
BCBS Illinois BlueChoice Select
BCBS Illinois HMO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Health Care PPO Platinum
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment